Allakos Inc (ALLK)
ALLK
Immunology
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Immunologysrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet Infect Dis 2026 Aug 31 PMID 42673984
- Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial. — JAMA Pediatr 2026 Jul 27 PMID 42507431
- Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. — Nat Med 2026 Aug PMID 42493571
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. — Lancet Gastroenterol Hepatol 2026 Aug PMID 42341804
- A cross-sectional study of oxidative stress pathway genotypes and their interactions with environmental pollutant levels identifies associations with gene expression and lung function. — EBioMedicine 2026 Jul PMID 42336761
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Allakos Inc.
Full ALLK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.